Cytovale Builds Momentum With New IntelliSep Sepsis Data and Policy-Aligned ED Strategy

Cytovale, a San Francisco–based diagnostics company focused on early sepsis detection, saw a data-driven week as it advanced the clinical and commercial case for its FDA-cleared IntelliSep test. New multicenter outcomes and behavioral data reinforced the platform’s role in reshaping emergency department decision-making and hospital sepsis strategy.

In a peer-reviewed JACEP Open study using 100 real patient cases, adding IntelliSep results to standard ED data changed or reinforced emergency physicians’ diagnostic decisions in 86% of 1,040 evaluations. The rapid, eight-minute host-response test also improved diagnostic accuracy and boosted physician confidence by 19%, underscoring its potential as a core workflow tool.

Real-world multicenter outcomes from the Franciscan Missionaries of Our Lady Health system showed IntelliSep deployment in more than 34,000 ED patients was associated with over a 20% reduction in sepsis-related mortality and resource use. The data included a 19% relative drop in sepsis mortality, increased discharges without higher revisit rates, and a 30% reduction in blood culture utilization.

Cytovale also reiterated prior results from Froedtert Hospital, where IntelliSep implementation correlated with a 42% mortality reduction in ED patients with suspected infection. These findings collectively position IntelliSep as a lever for earlier risk identification, faster treatment initiation, and more targeted resource allocation in acute care settings.

The company amplified its message through Becker’s Healthcare webinars that frame sepsis risk management as a strategic hospital priority rather than a compliance task. By aligning IntelliSep with evolving SEP-1 measures, value-based purchasing and capacity constraints, Cytovale is targeting C-suite, quality and finance leaders as key decision-makers.

Cytovale’s communications also highlighted its emphasis on supporting emergency physicians with faster, clearer decision-support in high-acuity environments. The firm linked its strategy to National Doctors’ Day themes and stressed host-response diagnostics as a way to navigate infectious-disease complexity, aiming to standardize risk assessment across diverse emergency departments.

Thought-leadership content referencing UCLA bioengineering professor Dino Di Carlo, who helped launch the IntelliSep platform, underscored the company’s roots in academic collaboration and patient-centered design. This focus on clinically meaningful innovation may help Cytovale attract partners and talent as it scales its technology.

Overall, the week underscored Cytovale’s effort to pair robust clinical and real-world evidence with policy-aligned messaging, strengthening IntelliSep’s value proposition in sepsis diagnostics. The accumulating data and strategic positioning appear geared toward driving broader hospital adoption and supporting reimbursement discussions going forward.